Nano Intelligence Biomedical Engineering Corp. (NIBEC) said Thursday that it has completed pre-clinical trials for its peptide-based osteoporosis treatment and plans apply for non-clinical and phase 1 clinical trials.

For the past year, NIBEC has demonstrated safety and efficacy of the treatment at the Laboratory of Pharmacology and Toxicology (LPT), a global GLP-certified preclinical testing laboratory, in Germany.

If existing drugs for osteoporosis treatment were effective in suppressing bone resorption, NIBEC’s osteoporosis drug is a breakthrough treatment that has a bone-resorption-inhibiting function along with peptide-based bone resorption, it said. Also, compared to conventional hormone medications that could only last two years, the company’s peptide-based treatment has no limits, it added.

NIBEC’s osteoporosis treatment is also effective against post-menopausal women, as it has the effect of treating osteoporosis as well as inhibiting subcutaneous fat accumulation.

“The result of the pre-clinical trial is meaningful as the company plans to enter the pharmaceutical market, starting with peptide-based osteoporosis medicine,” a company official said. “We plan to accelerate the preparations for submitting investigational new drug application by the second half of this year and starting clinical trials for next year.”